Vitamin A and Azithromycin for Acne Vulgaris
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03090048 |
Recruitment Status : Unknown
Verified February 2021 by DR. VINOD C TAWAR, Manchanda Medical Clinic.
Recruitment status was: Not yet recruiting
First Posted : March 24, 2017
Last Update Posted : February 25, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acne Vulgaris | Drug: Vitamin A Drug: Azithromycin | Early Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 30 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Investigator) |
Primary Purpose: | Treatment |
Official Title: | Treatment of Acne for Cases Resistant to Currently Available Measures Via Vitamin A With or Without Azithromycin in Topical Formulations |
Estimated Study Start Date : | April 1, 2021 |
Estimated Primary Completion Date : | August 24, 2021 |
Estimated Study Completion Date : | October 31, 2021 |
![](/ct2/html/images/NIH_NLM_ABRV_BLK_4.png)
Arm | Intervention/treatment |
---|---|
Experimental: Vitamin A
retinyl palmitate USP
|
Drug: Vitamin A
Vitamin A 2-3 % concentration
Other Name: retinyl palmitate |
Experimental: Azithromycin with Vitamin A
USP grade ingredients
|
Drug: Vitamin A
Vitamin A 2-3 % concentration
Other Name: retinyl palmitate Drug: Azithromycin azithromycin monohydrate
Other Name: azithromycin monohydrate |
Active Comparator: Azithromycin
azithromycin monohydrate
|
Drug: Azithromycin
azithromycin monohydrate
Other Name: azithromycin monohydrate |
- Measurement (dimensions) of acne lesions [ Time Frame: Every 4 weeks up to16 weeks ]follow-up focussed on observation of changes
![](/ct2/html/images/NIH_NLM_ABRV_BLK_4.png)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years to 45 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Patients with active lesions
Exclusion Criteria:
- Patients on a treatment
- Asymptomatic patients
![](/ct2/html/images/NIH_NLM_ABRV_BLK_4.png)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03090048
Contact: Vinod C Tawar, M.Sc., M.D. | 604 754 2235 | Tawar.vinod@yahoo.com |
Canada, British Columbia | |
Manchanda Mc | |
Surrey, British Columbia, Canada, V3W2T2 | |
Contact: VINOD TAWAR, MD 604 754 2235 TAWAR.VINOD@YAHOO.COM |
Study Director: | Vinod C Tawar | M.D. |
Responsible Party: | DR. VINOD C TAWAR, Principal investigator, Manchanda Medical Clinic |
ClinicalTrials.gov Identifier: | NCT03090048 |
Other Study ID Numbers: |
Tawar -1 |
First Posted: | March 24, 2017 Key Record Dates |
Last Update Posted: | February 25, 2021 |
Last Verified: | February 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Acne Vulgaris Acneiform Eruptions Skin Diseases Sebaceous Gland Diseases Vitamin A Azithromycin Retinol palmitate Vitamins Micronutrients |
Physiological Effects of Drugs Anti-Bacterial Agents Anti-Infective Agents Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Anticarcinogenic Agents Antineoplastic Agents |